LT2904009T - Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška - Google Patents

Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška

Info

Publication number: LT2904009T
Authority: LT; Lithuania
Prior art keywords: herv; expression; treating; compounds; diseases associated
Prior art date: 2012-10-02

Application number

LTEP13770926.7T

Other languages

English (en)

Inventor

Hervé Perron

Reza FIROUZI

Patrick KÜRY

Raphaël FAUCARD

Alexandra MADEIRA

Julie Joanou

Original Assignee

Geneuro Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-02

Filing date

2013-10-01

Publication date

2019-03-12

2013-10-01 Application filed by Geneuro Sa filed Critical Geneuro Sa

2019-03-12 Publication of LT2904009T publication Critical patent/LT2904009T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Oncology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

LTEP13770926.7T 2012-10-02 2013-10-01 Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška LT2904009T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261708779P	2012-10-02	2012-10-02
US201261746792P	2012-12-28	2012-12-28
PCT/EP2013/070452 WO2014053489A1 (en)	2012-10-02	2013-10-01	Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein

Publications (1)

Publication Number	Publication Date
LT2904009T true LT2904009T (lt)	2019-03-12

Family

ID=49274655

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP13770926.7T LT2904009T (lt)	2012-10-02	2013-10-01	Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška
LTEP18198309.9T LT3447070T (lt)	2012-10-02	2013-10-01	Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP18198309.9T LT3447070T (lt)	2012-10-02	2013-10-01	Junginiai, skirti gydyti remielinizacijos blokadą, sergant ligomis, susijusiomis su herv-w apvalkalo baltymo raiška

Country Status (31)

Country	Link
US (2)	US9840550B2 (lt)
EP (2)	EP2904009B1 (lt)
JP (2)	JP6379331B2 (lt)
KR (1)	KR102098033B1 (lt)
CN (2)	CN105709224B (lt)
AU (2)	AU2013326552B2 (lt)
BR (1)	BR112015007150A8 (lt)
CA (1)	CA2882781C (lt)
CY (2)	CY1121237T1 (lt)
DK (2)	DK2904009T3 (lt)
EA (2)	EA037253B1 (lt)
EC (1)	ECSP15014925A (lt)
ES (2)	ES2878248T3 (lt)
HR (2)	HRP20190274T1 (lt)
HU (2)	HUE043419T2 (lt)
IL (3)	IL237474A0 (lt)
IN (1)	IN2015DN02397A (lt)
LT (2)	LT2904009T (lt)
MX (2)	MX385003B (lt)
MY (1)	MY172209A (lt)
PL (2)	PL2904009T3 (lt)
PT (2)	PT3447070T (lt)
RS (2)	RS58320B1 (lt)
RU (1)	RU2636355C2 (lt)
SA (1)	SA515360207B1 (lt)
SG (1)	SG11201501274VA (lt)
SI (2)	SI3447070T1 (lt)
SM (1)	SMT201900087T1 (lt)
UA (1)	UA119032C2 (lt)
WO (1)	WO2014053489A1 (lt)
ZA (1)	ZA201501491B (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2949342A1 (en) *	2014-05-28	2015-12-02	Geneuro SA	Antiretroviral drug targeting human endogenous retrovirus
EP3351265A1 (en) *	2017-01-20	2018-07-25	Geneuro SA	Anti-herv-k envelope antibody and uses thereof
WO2018159787A1 (ja)	2017-03-01	2018-09-07	国立大学法人北海道大学	疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2020045683A1 (ja) *	2018-09-01	2020-03-05	国立大学法人北海道大学	ストレス負荷が関与する疾患を予防及び／又は治療するための医薬
WO2021044009A1 (en) *	2019-09-04	2021-03-11	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies
CN121873239B (zh) *	2026-03-18	2026-06-30	中国人民解放军军事科学院军事医学研究院	一种抗人mbp单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2753098B1 (fr) *	1996-09-06	1998-11-27	Sod Conseils Rech Applic	Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
EP1265989A2 (en) *	2000-03-21	2002-12-18	MS Research A/S	An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
EP1361892A4 (en)	2001-01-17	2004-10-13	Trubion Pharmaceuticals Inc	BINDING DOMAIN FUSION PROTEIN Immunoglobulin
FR2865403B1 (fr) *	2004-01-23	2009-06-12	Biomerieux Sa	Composition pour le traitement d'une pathologie associee a la msrv/herv-w
US20090233888A1 (en) *	2005-03-23	2009-09-17	Usc Stevens, University Of Southern California	Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US8410115B2 (en) *	2006-02-28	2013-04-02	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE032251T2 (en) *	2007-02-08	2017-09-28	Biogen Ma Inc	Neuroprotection in demyelinating diseases
CA2705435A1 (en) *	2007-11-12	2009-05-22	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
DK3211005T3 (da)	2008-07-08	2021-06-07	Geneuro Sa	Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
EP2355660A4 (en) *	2008-10-13	2012-05-02	Biovista Inc	COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
WO2010148323A2 (en) *	2009-06-18	2010-12-23	Whittemore Peterson Institute For Neuro-Immune Disease	Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus
DK2533634T3 (en) *	2010-02-12	2016-01-25	Biogen Ma Inc	NEURO PROTECTIVE demyelinating diseases

2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en not_active Ceased
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko not_active Expired - Fee Related
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 MX MX2019008916A patent/MX385003B/es unknown
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh not_active Expired - Fee Related
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja not_active Expired - Fee Related
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 SM SM20190087T patent/SMT201900087T1/it unknown
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 US US14/429,199 patent/US9840550B2/en not_active Expired - Fee Related
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh not_active Expired - Fee Related
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en not_active Ceased
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 HR HRP20190274TT patent/HRP20190274T1/hr unknown
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja not_active Expired - Fee Related
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en not_active Ceased
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown

Also Published As

Publication number	Publication date
ECSP15014925A (es)	2017-07-31
LT3447070T (lt)	2021-06-10
CN105709224B (zh)	2020-06-05
DK2904009T3 (en)	2019-03-11
HUE054051T2 (hu)	2021-08-30
IN2015DN02397A (lt)	2015-09-04
IL237474A0 (en)	2015-04-30
US10752675B2 (en)	2020-08-25
EA201791525A2 (ru)	2018-07-31
HK1221399A1 (zh)	2017-06-02
CY1124378T1 (el)	2022-07-22
MX366846B (es)	2019-07-26
JP2018065814A (ja)	2018-04-26
MX2019008916A (es)	2019-11-11
CY1121237T1 (el)	2020-05-29
CN104684927A (zh)	2015-06-03
AU2018217328B2 (en)	2019-09-19
KR102098033B1 (ko)	2020-04-08
MX385003B (es)	2025-03-14
ES2710748T3 (es)	2019-04-26
US20180066040A1 (en)	2018-03-08
BR112015007150A8 (pt)	2018-02-06
CA2882781C (en)	2021-06-15
SG11201501274VA (en)	2015-05-28
RS58320B1 (sr)	2019-03-29
IL264382A (en)	2019-02-28
ZA201501491B (en)	2016-01-27
RU2015116149A (ru)	2016-11-27
KR20150064147A (ko)	2015-06-10
PL2904009T3 (pl)	2019-06-28
AU2018217328A1 (en)	2018-09-06
IL274047B (en)	2020-11-30
EA201791525A3 (ru)	2018-12-28
JP2016500651A (ja)	2016-01-14
EA028245B1 (ru)	2017-10-31
BR112015007150A2 (pt)	2017-07-04
RS61794B1 (sr)	2021-06-30
JP6379331B2 (ja)	2018-08-29
EA037253B1 (ru)	2021-02-26
AU2013326552A1 (en)	2015-03-05
ES2878248T3 (es)	2021-11-18
CN104684927B (zh)	2018-06-19
SI2904009T1 (sl)	2019-04-30
EP2904009A1 (en)	2015-08-12
US9840550B2 (en)	2017-12-12
PT2904009T (pt)	2019-02-19
PL3447070T3 (pl)	2021-09-06
AU2013326552B2 (en)	2018-05-24
EP3447070A1 (en)	2019-02-27
MY172209A (en)	2019-11-15
RU2636355C2 (ru)	2017-11-22
SA515360207B1 (ar)	2018-09-18
EA201590678A1 (ru)	2015-07-30
WO2014053489A1 (en)	2014-04-10
PT3447070T (pt)	2021-05-19
CA2882781A1 (en)	2014-04-10
CN105709224A (zh)	2016-06-29
SI3447070T1 (sl)	2021-08-31
EP3447070B9 (en)	2021-08-11
MX2015003572A (es)	2015-08-20
HUE043419T2 (hu)	2019-08-28
US20150218256A1 (en)	2015-08-06
SMT201900087T1 (it)	2019-02-28
JP6538138B2 (ja)	2019-07-03
EP2904009B1 (en)	2018-11-21
UA119032C2 (uk)	2019-04-25
IL264382B (en)	2020-05-31
HRP20190274T1 (hr)	2019-04-05
HRP20210779T1 (hr)	2021-09-17
EP3447070B1 (en)	2021-02-24
DK3447070T3 (da)	2021-05-10
IL274047A (en)	2020-06-30

Publication	Publication Date	Title
IL274047B (en)	2020-11-30	Compounds for the treatment of blocking myelin regeneration in diseases associated with the expression of the envelope protein herv-w
AP2014007533A0 (en)	2014-03-31	Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
ZA201404873B (en)	2018-12-19	Enhancement of transport of therapeutic molecules across the blood brain barrier
DK3292875T3 (en)	2020-08-03	Compositions and methods for treating diseases
SG10201703677VA (en)	2017-06-29	Methods of treating s. aureus-associated diseases
IL233225A0 (en)	2014-08-31	Methods and formulations for the treatment of sialic acid deficiencies
IL238592A0 (en)	2015-06-30	Methods for treating liver diseases
LT2872176T (lt)	2017-07-10	Karboranilporfirinai, skirti naudoti vėžio gydymui
HUP1100290A2 (en)	2012-12-28	Combination compositions for the treatment of proliferative diseases
ZA201408474B (en)	2015-12-23	Novel proteins for the treatment of cellulosic material
IL234796B (en)	2018-02-28	Compounds for the treatment of diseases related to ischemia-reperfusion
SI2617412T1 (sl)	2016-04-29	Sestavek za topično zdravljenje
HUE048942T2 (hu)	2020-09-28	Antraciklin-származékok tumorbetegségek kezeléséhez
HUP1300025A2 (hu)	2014-07-28	Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása